Discovery of a novel and potent class of FabI-directed antibacterial agents.

Antimicrobial Agents and Chemotherapy
D J. PayneW F Huffman

Abstract

Bacterial enoyl-acyl carrier protein (ACP) reductase (FabI) catalyzes the final step in each elongation cycle of bacterial fatty acid biosynthesis and is an attractive target for the development of new antibacterial agents. High-throughput screening of the Staphylococcus aureus FabI enzyme identified a novel, weak inhibitor with no detectable antibacterial activity against S. aureus. Iterative medicinal chemistry and X-ray crystal structure-based design led to the identification of compound 4 [(E)-N-methyl-N-(2-methyl-1H-indol-3-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide], which is 350-fold more potent than the original lead compound obtained by high-throughput screening in the FabI inhibition assay. Compound 4 has exquisite antistaphylococci activity, achieving MICs at which 90% of isolates are inhibited more than 500 times lower than those of nine currently available antibiotics against a panel of multidrug-resistant strains of S. aureus and Staphylococcus epidermidis. Furthermore, compound 4 exhibits excellent in vivo efficacy in an S. aureus infection model in rats. Biochemical and genetic approaches have confirmed that the mode of antibacterial action of compound 4 and related compounds is via i...Continue Reading

References

Aug 26, 1998·Nature·L M McMurryS B Levy
Nov 7, 1998·The Journal of Biological Chemistry·R J HeathC O Rock
Jul 26, 2000·Nature·R J Heath, C O Rock
Feb 24, 2001·International Journal of Antimicrobial Agents·R BaxJ Verhoef
Jun 22, 2001·The Journal of Antimicrobial Chemotherapy·C Slater-RadostiD D Jaworski
Jul 12, 2002·Journal of Medicinal Chemistry·William H MillerWilliam F Huffman

❮ Previous
Next ❯

Citations

Sep 25, 2010·Applied Microbiology and Biotechnology·Stefano DonadioDaniela Jabes
Nov 23, 1992·Biochimica Et Biophysica Acta·M GutmannR Krämer
Jul 17, 1995·Biochimica Et Biophysica Acta·R P Oude ElferinkG M Groothuis
Aug 12, 2010·Journal of Medicinal Chemistry·Suresh K TipparajuRima L McLeod
May 19, 2011·The Journal of Antibiotics·Mark S Butler, Matthew A Cooper
Sep 5, 2013·The Journal of Antibiotics·Mark S ButlerMatthew A Cooper
Apr 8, 2006·Nature Biotechnology·Molly B Schmid
Dec 13, 2006·Nature Reviews. Drug Discovery·David J PayneDavid L Pompliano
Sep 17, 2004·Nature Reviews. Microbiology·Molly B Schmid
Aug 31, 2011·Proceedings of the National Academy of Sciences of the United States of America·Joshua B ParsonsCharles O Rock
Mar 14, 2009·The Journal of Antimicrobial Chemotherapy·Chang Ji ZhengWon-Gon Kim
Jun 28, 2011·The Journal of Antimicrobial Chemotherapy·David M Livermore
Feb 23, 2013·The Journal of Antimicrobial Chemotherapy·Krishan Kumar, Sidharth Chopra
Mar 1, 2007·Acta Crystallographica. Section D, Biological Crystallography·Stephen P MuenchDavid W Rice
Jun 7, 2006·Acta Crystallographica. Section F, Structural Biology and Crystallization Communications·Jun SaitoYasuo Takeuchi
Mar 3, 2007·Acta Crystallographica. Section F, Structural Biology and Crystallization Communications·Kook-Han KimEunice EunKyeong Kim
Jul 28, 2006·Antimicrobial Agents and Chemotherapy·Sho TakahataShigeru Hoshiko
Jun 3, 2009·Antimicrobial Agents and Chemotherapy·James A KarlowskyGeorge G Zhanel
Sep 19, 2007·Antimicrobial Agents and Chemotherapy·Tatiana BogdanovichPeter C Appelbaum
Sep 6, 2012·Antimicrobial Agents and Chemotherapy·Nachum KaplanHenry W Pauls
Mar 6, 2013·Antimicrobial Agents and Chemotherapy·Joshua B ParsonsCharles O Rock
Oct 18, 2002·Antimicrobial Agents and Chemotherapy·Frank FanDavid J Payne
May 23, 2003·Antimicrobial Agents and Chemotherapy·Anthony E ChoudhryKapila Ratnam
Apr 24, 2004·Antimicrobial Agents and Chemotherapy·Losee L LingDonald T Moir
Jan 15, 2011·Clinical Microbiology Reviews·Lynn L Silver
Dec 3, 2009·Biological & Pharmaceutical Bulletin·Yun-Ju KwonWon-Gon Kim
Dec 20, 2003·Pharmacogenomics·Dezhong YinYinduo Ji
Nov 29, 2007·Future Microbiology·Knut Ohlsen, Udo Lorenz
Sep 19, 2012·EMBO Molecular Medicine·Ruben C HartkoornStewart T Cole
Jul 23, 2004·Expert Opinion on Investigational Drugs·Alex J O'Neill, Ian Chopra
Jul 31, 2012·Current Opinion in Pharmacology·Donald T MoirTerry L Bowlin
Jun 19, 2012·International Journal of Antimicrobial Agents·Rungtip Chuanchuen, Herbert P Schweizer
Aug 25, 2011·Current Opinion in Microbiology·Joshua B Parsons, Charles O Rock

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

© 2022 Meta ULC. All rights reserved